These re-engineered T-cells are then transfused back into the patient, where they can begin attacking leukemia.

这些改造过的T细胞会被输回患者体内，对抗白血病。

Studies have shown that 83 percent of patients responded to the treatment, achieving remission within three months, Novartis said.

诺华称，研究发现，治疗对83%的患者有效，患者的病情在三个月内成功得到了缓解。

An application with the European Medicines Agency is expected to be filed by the end of the year.

诺华预计将于今年年底向欧洲药品管理局提出申请。

The price of Kymriah - which is delivered to a patient just once - is $475,000, said Bruno Strigini, CEO of Oncology at Novartis.

诺华肿瘤事业部CEO布鲁诺?斯蒂格尼说，Kymriah的价格是每次治疗47.5万美元。

Patients who do not respond to the treatment within the first month would not be expected to pay, he told reporters.

他对记者说，如果治疗一个月内对患者无效，那么患者无需付款。

The more common treatment for leukemia - bone marrow transplants - can cost between $540,000 and $800,000 the first year in the United States, Strigini said.

斯蒂格尼说，白血病更常见的治疗方法是骨髓移植法，第一年骨髓移植的价格在美国通常介于54万美元到80万美元之间。

【首个白血病治疗基因疗法在美获批】相关文章：

★ 外媒评《流浪地球》：看到了异于西方大片的价值观

★ 头发乱蓬蓬的小男孩

★ 28岁前应该尽早知道的16个道理

★ 讲讲你见过最差劲的老师

★ 分手后把前任从照片上P掉，这个服务可以有

★ IQ测的只是智力吗？

★ 有话不敢说怎么破?

★ 戴妃车祸纪录片引争议 将在戛纳上映

★ 为什么抱臂能帮助抑制疼痛

★ 中国驻外使馆开通支付宝和微信支付